Biocryst Archives - Page 3 of 5 - Biocryst

Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Oral Once-Daily Berotralstat for the Prevention of Hereditary Angioedema Attacks: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Informed Decision-Making in Hereditary Angioedema Prophylaxis

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
The current situation of hereditary angioedema patients in Germany: results of an online survey

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Patient and Caregiver Perspectives on Oral Transition in the Emerging Hereditary Angioedema Treatment Landscape

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Population Pharmacokinetic Modeling and Simulations of Berotralstat for Prophylactic Treatment of Attacks of Hereditary Angioedema

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Long-Term Safety and Effectiveness of Berotralstat for Hereditary Angioedema: The Open-Label APeX-S Study

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)